

**DEVELOPMENT OF A MINIATURE MASS SPECTROMETER AND
IONIZATION METHODS FOR DIRECT SMALL BIOMOLECULE
ANALYSIS**

by

Xiao Wang

A Dissertation

Submitted to the Faculty of Purdue University

In Partial Fulfillment of the Requirements for the degree of

Doctor of Philosophy



Weldon School of Biomedical Engineering

West Lafayette, Indiana

December 2017

ProQuest Number: 10638169

All rights reserved

INFORMATION TO ALL USERS

The quality of this reproduction is dependent upon the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



ProQuest 10638169

Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author.

All rights reserved.

This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.

ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, MI 48106 – 1346

THE PURDUE UNIVERSITY GRADUATE SCHOOL
STATEMENT OF COMMITTEE APPROVAL

Dr. Zheng Ouyang, Co-Chair

Weldon School of Biomedical Engineering

Dr. Fang Huang, Co-Chair

Weldon School of Biomedical Engineering

Dr. Riya Shi

Weldon School of Biomedical Engineering

Dr. Yu Xia

Department of Chemistry

Approved by:

Dr. George R. Wodicka

Head of the Graduate Program

For the time to be memorized

ACKNOWLEDGMENTS

I still remember the first night that I arrived at Purdue five years ago. It was a new start and a new world for me. Time flies and it is time to start again. I really appreciate all the people I met and accompanied during the past five years.

Firstly, I would like to thank Dr. Zheng Ouyang who is my advisor for the last five years. He is the person who brought me to the world of mass spectrometry, ambient ionization and portable instrumentation. His persistence inspired and encouraged me to pursue my own goals. He instructed me how to present research works and how to communicate with others. Also, he shared his life experiences with us when we met difficulties and helped me to get through any troubles.

I would also thanks Dr. Fang Huang as my co-chair of the committee and Dr. Riyi Shi and Dr. Yu Xia as my committees. They offered a lot to help my research and career development. I would also thanks Professor Graham R. Cooks for his kind and supportive help.

Special acknowledgements to Dr. Yue Ren, Dr. Linfan Li and all the people who make significant contributions to the development of Mini β mass spectrometer. I would also thank Purspec technologies and thank the people there, including but not limited to: Ang Li, Xinwei Liu, Kai Liu, who made the first Mini β work possible.

I would also like to give special thanks to all the group members in Purdue Ouyang's lab, Purdue Aston lab, Purdue Xia's lab, and the MS lab in Tsinghua University. It is really my pleasure to work with all of the talented people there. Dr. Tsung-Chi Chen helped me to know how to use miniature mass spectrometer, Dr. Ziqing Li taught me the chemistry in MS world, Dr. Anyin Li helps me with nano-electrospray ion source and Dr. Pu Wei about how to prepare the solution for analysis.

TABLE OF CONTENTS

TABLE OF CONTENTS.....	v
LIST OF TABLES.....	viii
LIST OF FIGURES	ix
LIST OF ABBREVIATIONS.....	xiv
ABSTRACT.....	xv
1. INTRODUCTION	1
1.1 Precision Medicine and Biomarker Analysis.....	1
1.2 Technologies for Small Biomolecule Analysis and Clinical Applications.....	4
1.3 Ambient Ionization and Miniature Mass Spectrometer.....	6
1.3.1 Ambient Ionization	7
1.3.1.1 Paper Spray.....	9
1.3.1.2 Extractive Nano-electrospray	12
1.3.1.3 Paper-Capillary Spray.....	13
1.3.1.4 Slug Flow Micro Extraction	14
1.3.2 Portable Mass Spectrometer	16
1.3.2.1 Miniature Ion Traps	18
1.3.2.2 Vacuum System for Ion Trap Miniature Mass Spectrometers	20
1.3.2.3 Mini12, A Point-of-care Miniature Mass Spectrometry System	22
1.3.2.4 Dual-Trap Mass Spectrometer.....	24
1.4 Conclusion	25
1.5 References.....	27
2. ON-DEMAND PRESSURE CONTROL OF A PORTABLE DUAL-LINEAR ION TRAP MASS SPECTROMETER WITH STATE-OF-THE-ART PUMPING SYSTEM.....	35
2.1 Introduction.....	35
2.2 Instrumentation Design.....	38
2.3 Study of The Isolation Response and The In-trap Collision Induced Dissociation Response	42
2.4 Study of Ion Transfer Efficiency of a Dual-Trap System.....	48
2.4.1 Pressure Optimization of Transfer Efficiency	49

2.4.2	Ejection Q-value Optimization	50
2.4.3	Trapping Q-value Optimization.....	51
2.4.4	Excitation Energy Optimization	52
2.4.5	Excitation Duration Optimization.....	53
2.5	New Vacuum Design with Additional Gas Injection	54
2.6	Conclusion	58
2.7	References	59
3.	DESIGN, MANUFACTURE AND CHARACTERIZATION OF A NEW PORTABLE MASS SPECTROEMETER SYSTEM WITH PAPER-CAPILLARY SPRAY ION SOURCE.	61
3.1	Introduction.....	61
3.2	Instrumentation Design.....	63
3.2.1	Vacuum Design	66
3.2.2	Digital Control Design.....	67
3.2.3	Software Design.....	67
3.3	Instrumentation Characterization.....	69
3.3.1	Single Trap Characterization	69
3.3.2	Direct Protein, Lipid and Peptide Analysis	73
3.4	Dual Trap Characterization.....	75
3.5	Ion Source and Cartridge Optimization	78
3.6	Direct Analysis of Using Paper Capillary Spray Cartridge	79
3.7	Conclusion	82
3.8	References	83
4.	DIRECT ANALYSIS OF NON-VOLATILE CHEMICALS ON SURFACE USING SYNCHRONIZED DISCHARGE IONIZATION AND HANDHELD MASS SPECTROMETERS	86
4.1	Introduction.....	86
4.2	Experimental Section	88
4.3	Instrumentation	88
4.4	Results and Discussion	92
4.4.1	Selection of Chemicals	92
4.4.2	Direct sampling of nonvolatile chemicals on surface in negative ion mode	92

4.4.3	Surface sampling in negative ion mode with heated sampling gas	96
4.4.4	Surface sampling in positive ion mode with heated sampling gas and reagent.....	97
4.4.5	Real samples and large area sampling	99
4.5	Conclusions.....	101
4.6	References.....	102
PUBLICATIONS.....		105

PREVIEW

LIST OF TABLES

Table 1. The classification of clinical biomarker uses and objectives (reprint from reference) ¹⁸ ..	4
Table 2. Selected ambient ionization methods	8
Table 3, Summary of the characteristics of the Mini β instrument in single trap mode.	72
Table 4. List of the chemical compounds selected for testing in the experiments.	91

PREVIEW

LIST OF FIGURES

Figure 1. The definition and classification of biological analysis.	2
Figure 2. Procedure of paper spray ionization. ³⁵	10
Figure 3. A1, A2, A3 The design of the first paper spray cartridge ⁴⁰ . B, The cartridge designed for Mini12 mass spectrometer ⁵⁵ . C, The paper spray high throughput design ⁵⁶	11
Figure 4. A. Photo of nano-extractive spray. B. Schematic of nano-extractive spray.	13
Figure 5. Schematic of paper-capillary spray ion source. Insertion is a photo of paper capillary spray to analyses of 3 μ l dried blood spot.	14
Figure 6. Schematic and operation concept of slug flow micro extraction.	15
Figure 7. Demonstration of different kinds of modified ion traps. (Reprint from Reference ⁷²)...	19
Figure 8. A. The schematic of the discontinuous atmospheric interface (DAPI). The first DAPI is tested on a RIT portable mass spectrometer. B the pressure variation curve of the vacuum chamber and DAPI working principle.	21
Figure 9. A) Protocol for POC analysis using paper spray cartridge. B) Configuration of Mini 12 system. C) Configuration of paper spray cartridge for Mini 12 system. D) Spectrum of 50 ng/ml amitriptyline in blood using paper spray ionization. E) Spectrum of 50 ng/ml amitriptyline in blood using extractive spray ionization. F) Quantitative analysis of amitriptyline and amitriptyline-D6 using both paper spray and extractive spray ionization.	23
Figure 10. The drawing of the instrumentation used in this research.	38
Figure 11. The measured pressure of the vacuum chamber as a function of time. Pinch valve is opened at a frequency of 0.5Hz, A) Pinch valve opens 10ms during each opening. B) Pinch valve opens 40ms during each opening.	40
Figure 12. Pressure variations of a single pinch valve opening.	41
Figure 13. Green line indicates the pressure in vacuum chamber as a function of time. Orange line indicates the isolation efficiency as a function of time. Blue line indicates the CID efficiency as a function of time.	44
Figure 14. A, isolation efficiency and CID efficiency as a function of pressure. B, C and D, spectrum of isolated verapamil at m/z 455 in different pressure, which corresponding to the three green lines in A. Intensity is normalized by the highest intensity. E, F and	

G, spectrum of CID verapamil at m/z 455 in different pressure, which corresponding to the three green lines in A. Intensity is normalized by the highest intensity.....	45
Figure 15. Drawing of isolation, CID efficiency and pressure as a function of time for different pumping operation condition. A, Hipace-10 pump. B, Hipace-30 pump with 50% rotation speed. C, Hipace-30 with 75% rotation speed. D, Hipace-30 with 75% connector area blocked.	47
Figure 16. Transfer efficiency of the dual-QLIT as a function of pressure.	50
Figure 17. Transfer efficiency of the dual-QLIT as a function of the trapping q -value of the first ion trap.	51
Figure 18. Transfer efficiency of the dual-QLIT as a function of the trapping q -value of the second ion trap.	52
Figure 19. Transfer efficiency of the dual-QLIT as a function of excitation energy of the first ion trap.	53
Figure 20. Transfer efficiency of the dual-QLIT as a function of the excitation duration on the first ion trap.	54
Figure 21. The drawing of the pressure curve of different DAPI operation mode. Black, normal DAPI operation, only the first DAPI is used. Red, second DAPI opened to maintain the pressure at high 6×10^{-4} torr for a second. Blue, second DAPI opened to maintain the pressure at 10^{-2} torr for 700 milliseconds.	55
Figure 22. A. The drawing of the pressure curve of different DAPI operation mode. Four different color stars represents the four time points that MSAT and CID are conducted starting from the represented pressure condition. B. Spectrum of Verapamil MS^2 spectrum that MSAT and CID at the blue star. C. Spectrum of Verapamil MS^2 spectrum that MSAT and CID at the black star. D. Spectrum of Verapamil MS^2 spectrum that MSAT and CID at the purple star. E. Spectrum of Verapamil MS^2 spectrum that MSAT and CID at the red star.	56
Figure 23. A. A picture of the working instrument. The instrument works with a sampling tool, a paper-capillary spray cartridge and a solvent bottle. B. Schematic of the Mini β mass spectrometer. The instrument consists of four parts, the vacuum system (vacuum chamber, turbo pump, diaphragm pump and DAPI), RF system (RF coil and RF power amplifier), control system (digital control and screen) and ion source.	65

Figure 24. Schematic of the core components. The three gates and two quadrupoles assembled as two ion traps followed by an electron multiplier detector.	66
Figure 25. Schematic of the system signal control.	67
Figure 26. User interface of the software.....	68
Figure 27. A. Mass spectrum of 900ng/ml acidic red in MeOH. B. Spectrum of standard Ultramark calibration solution. C. Spectrum of 900 ng/ml Clenbuterol in MeOH. The scan speed is 1000 Da/s. D. Spectrum of 900ng/ml Clenbuterol in MeOH. The scan speed is 8000 Da/s.....	70
Figure 28. A. Spectrum of MS ⁴ of Clenbuterol. B. Spectrum of MS ⁵ of Clenbuterol in MeOH. C. Spectrum of 30 ng/mL Verapamil in MeOH using nano-electrospray ionization. D. Spectrum of 10ul of 20 ng/mL Verapamil in MeOH using paper capillary spray cartridge.....	71
Figure 29. A. Mass spectrum of MS ² analysis of Bradykinin in MeOH:H ₂ O at 50:50. B. Mass spectrum of MS ² analysis of Angiopoietin-2 in MeOH:H ₂ O at 50:50. C. Mass spectrum of MS ² analysis of PC in MeOH:H ₂ O 90:10. D. Mass spectrum of MS ² analysis of PE in MeOH:H ₂ O 90:10. E. Mass spectrum of MS ² analysis of Insulin in H ₂ O:HCOOH at 99:1. F. Mass spectrum of MS ² analysis of Cytochrome C in H ₂ O:HCOOH at 99:1.....	74
Figure 30. Demonstration of the dual-trap functionality. A. schematic of the central core components of the Mini β mass spectrometer. B. Scan function of the dual-trap system for the analysis of two target analyte. C. Demonstration of the four-step ion movement in a dual-trap system. D-G. spectra of the ions in the different steps of ion movements shown in C.....	76
Figure 31. Three representatives design of the paper-capillary spray cartridge. A. The window for solvent is located between the sample and high voltage connector. B. The protection cover is a flat surface instead of four antennas. C. The final design for paper capillary spray cartridge.	78
Figure 32. A, Picture of Golden cypress. B, Structure of Auramine O. C. Spectrum of 20 μ g/ml of Auramine O analyzed using PCS cartridge. D. Spectrum of the direct analysis of Golden cypress dyed by Auramine O using PCS cartridge.....	80

- Figure 33. Upper, MS/MS mass spectrum of the benzoylecgonine in synthetic urine detected by PCS cartridge and Mini β Mass spectrometer. Bottom, MS/MS spectrum of the detection of Phenformin in dietary powder. 81
- Figure 34. (a) Schematic of a hand-held mass spectrometer modified with a surface sampling probe. (b) Photograph of the sampler make from a stainless steel capillary. (c) Scan function for SDI MS analysis and the pressure variation in the vacuum manifold. The blue shadow area indicated the synchronization of pinch valve opening, sampling gas flow and discharge ionization..... 89
- Figure 35. MS spectra recorded in negative ion mode of (a) 300 ng of trinitrotoluene (TNT) deposited on a PTFE surface, inset for MS/MS spectrum of parent ion at m/z 227 and corresponding product ion at m/z 210 and 197. (b) 300 ng of fenitrothion deposited on a PTFE surface, inset for MS/MS spectrum of parent ion at m/z 262 and corresponding product ion at m/z 152 and 168. (c) 300 ng of malathion deposited on a PTFE surface, inset for MS/MS spectrum of parent ion at m/z 157 and corresponding product ion at m/z 142, and (d) 300 ng of tetryl deposited on a PTFE surface, inset for MS/MS spectrum of parent ion at m/z 241 and corresponding product ion at m/z 181, 213 and 241. 93
- Figure 36. Mass Spectrum of 300ng of Parathion-methyl detected on PTFE surface..... 94
- Figure 37. Demonstration of discharge condition control. (a) Waveform collected from oscilloscope: Blue stands for RF signal; pink stands for discharge current. Representing a mild discharge which was controlled in millisecond accuracy. (b) Spectrum collected corresponding to the discharge condition in (a). (c) Waveform collected from oscilloscope: Blue stands for RF signal; pink stands for discharge current. Representing a severe discharge which was controlled for about 40ms. (d) Spectrum collected corresponding to the discharge condition in (c). 95
- Figure 38 (a) MS spectra of cocaine in positive ion mode, with and without methanol vapor added as reagent. MS/MS Spectra recorded in positive ion mode of (b) cocaine, (c) atrazine, and (d) ketamine. 600 ng of each chemical compounds deposited on a PTFE surface 98
- Figure 39. (a) Photograph for direct sampling analysis of chemicals on an apple, 600 ng malathion deposited in the circled area of the apple. (b) MS/MS spectrum of the

detected malathion. (c) Schematic of the sample port for cotton swab. (d) MS/MS spectrum for the detection of 1 μg TNT in a 64 cm^2 area and (e) MS/MS spectrum for the detection of 900 ng THC in a 9 cm^2 area on a benchtop.	100
---	-----

PREVIEW

LIST OF ABBREVIATIONS

HGP: Human Genome Project

LOD: Limit-of-detection

LC: Liquid chromatography

GC: Gas chromatograph

MS: Mass spectrometry

MALDI: Matrix assisted laser desorption ionization

ESI: Electrospray Ionization

FDA: Food and Drug Administration

CT: Computed tomography

MRI: Magnetic Resonance Imaging

UV: Ultraviolet

DESI: Desorption electrospray ionization

RF: Radio Frequency

AC: Alternative Current

DC: Direct Current

DAPI: Discontinues Atmospheric Interface

ID: Inner Diameter

OD: Outer Diameter

SDI: Synchronized Discharge Ionization

ABSTRACT

Author: Wang, Xiao. PhD

Institution: Purdue University

Degree Received: December 2017

Title: Development of a Miniature Mass Spectrometer and Ionization Methods for Direct Small Biomolecule Analysis

Major Professor: Zheng Ouyang

Abstract

Precision medicine is one of the most popular topics in the world. The successful analysis of biomarkers and biomolecules in an accurate and precise way is key for precision medicine. Currently, most developed methods are focused on gene sequencing, proteomics or targeted molecular therapy. Qualitative and quantitative tests of small biomolecules are still lacking in attention. The rapid, direct analysis of small biomolecules with an accessible instrument is highly demanded. This study focuses on mass spectrometry based technologies that seek an easy-to-use and high throughput solution for direct biomolecule analysis.

The development of a portable mass spectrometer at Purdue has been underway for more than a decade. The miniature ion trap mass spectrometer can provide in-field analysis capability for a large variety of samples, such as drug molecules, lipids or peptides. Ionization methods such as paper spray, extractive spray and paper-capillary spray have been developed to couple with the miniature mass spectrometer. The advancement of ambient ionization facilitates real-time analysis using Miniature mass spectrometry. Taking advantage from the solid fundamental research done in Purdue, this study focuses on the development of a new miniature mass spectrometer system and new ionization methods for direct quantification of biomolecules. Firstly, a new vacuum design for the miniature mass spectrometer was constructed and tested. Using this new design, a

new miniature mass spectrometer, Mini β , was evaluated in detail. Lastly, a new ionization method was developed for the direct analysis of chemicals on surfaces.

The vacuum system is one of the most important systems in a mass spectrometer. For the miniature ion trap mass spectrometer developed in Purdue, a discontinuous atmospheric pressure interface (DAPI) is used with a Hipace-10 turbo pump. In this study, a new turbo pump, Hipace-30, is used to improve the pumping speed and analytical performance of the instrument. A dual-linear ion trap system is constructed using the new vacuum design. The pressure variation curve, isolation performance, collision induced dissociation efficiency and the mass selective axial transfer efficiency are studied in detail. The duty cycle of the new system is increased by a factor of three. Using the new turbo pump, a supplementary DAPI can be used to actively control the pressure in the vacuum chamber to a desired value which increases the ion manipulation efficiency.

A new miniature mass spectrometer, Mini β , has been designed and constructed based on the new pumping configuration with a dual quadrupole linear ion trap system. The analytical performance of the new system is evaluated in this study. As a linear ion trap mass spectrometer, the Mini β can achieve sub-ppb level of detection limit using nano-ESI and ppb level using paper capillary spray cartridge. Mini β has a resolving power higher than 700 with a scan speed of 1000Da/s and is capable to analyze both positive and negative ions with MS^n capability. The new system also demonstrates the possibility of analyzing biomolecules, including lipids, peptides and small proteins. A paper-capillary spray cartridge ion source has been designed to couple the new Mini β instrument. Using the new Mini β mass spectrometer with sample cartridge, the successful detection of illicit drug in urine and illegal additive in medicine has been demonstrated using real samples.

For the ionization and sampling method, a sampling probe is designed based on the DAPI system and an internal discharge ionization method has been evaluated. The ionization process is synchronized with the DAPI operation. Non-volatile chemicals with a vapor pressure around 10^{-4} torr on a surface can be directly analyzed. Sample with lower vapor pressure can still be analyzed by using a 1-watt heater to heat the sample gas. Methanol and water vapor were found to be effective to improve the ionization efficiency for analyte that generates protonated ions.

With the advanced vacuum and sample introduction technology, the new miniature mass spectrometer, Mini β , and the new ionization and sampling technology, portable mass spectrometer system can be further implemented into the precision medicine area for clinical applications.

1. INTRODUCTION

1.1 Precision Medicine and Biomarker Analysis

Every patient has unique characteristics. The living environment, medical history and genetic basis are pivotal factors that influence the diagnostic and treatment results of a patient¹. The concept of precision medicine dates back to the 19th century, where blood transfusions are based on the blood type of each patient. Since the first draft sequence of the human genome in 2001, precision medicine has become increasingly popular and effective, benefiting from scientific and technical advances. Precision medicine takes advantage of statistical results and divides patients into subpopulations based on their characteristics. This ensures the delivery of a tailored treatment at the right time to a specific patient²⁻³. Additionally, tailored medication treatment reduces treatment-related toxicity as well as expenses. Another aspect of precision medicine differentiates patients based on the susceptibility to a disease and provide advanced targeted prevention therapies. Disease can be controlled and treated in early stages to avoid further damage, increasing the patient's quality of life.

Biomarker tests⁴, as well as the biomolecule tests⁵, are key factors for the implementation of precision medicine. These biological analyses provide information from molecular to organ level which can guide medication actions. The advance of precision medicine requires these biological analyses to be more accurate and reliable. The collection of information and generation of a database for analysis results will improve method validation and clinical practice implementation. Precision medicine requires biomolecular tests to be precise and accurate to optimize treatment strategies for optimal outcomes. Furthermore, test results can provide researchers with valuable treatment efficacy data and highlight any potential health risks. These biomolecule tests also offer insight into the correlation between pivotal factors such as the environment, genetic and disease in

the long term. However, an inaccurate test or an improperly handled test will do more damage than before and can potentially be as problematic as a bad drug.




Figure 1. The definition and classification of biological analysis.

The concept of biomolecules and biomarkers share some similarity but also have their own focuses. As shown in Figure 1, biomarker tests emphasize more on the examination of biological indicators generated from human body, such as molecules, cells and even organs, which represent the status of various human diseases. Including molecules, cells and even organs. Biomolecule tests focus more on the analysis of various molecules in the human body, including endogenous molecules and exogenous molecules, such as pharmaceutical drugs, heavy metals and semisynthetic molecules. Exogenous molecular tests and metabolized exogenous molecular tests play a significant role in precision medicine which also works as a complement for biomarker tests.

Technologies have been developed to provide biomarker analysis in different scopes. Medical imaging including MRI, CT, PET and ultrasound are used for imaging organs *in vivo*, which provide guiding information for treatment. After the accomplishment of Human Genome Project (HGP)⁶ in 2003, high-throughput genomic sequencing technologies or called next-generation

sequencing⁷, was industrialized which provides production of thousands or millions of sequences simultaneously. Electrophoresis, protein chips, and liquid chromatography (LC) coupled with high resolution mass spectrometry, like time-of-flight mass spectrometry or orbitrap mass spectrometry help humans comprehend the importance of protein expression, structure and conformation. The advancement of LC-MS also benefits the analysis of lipid and small molecules in humans with high quantification accuracies and good limit-of-detections (LOD). Additionally, the use of matrix assisted laser desorption ionization with mass spectrometry (MALDI-MS)⁸ to analyze microorganisms has been approved by the US Food and Drug Administration (FDA)⁹⁻¹⁰.

Biomarker tests have several different uses in clinical practice (summarized in table 1). One biomarker test is used to understand a patient's molecular level and justify the status of the patient in a different domain. This information can be used as a patient's screening, diagnosis and classification evidence. Numerous biomarkers have been revealed to be highly correlated to some diseases including cardiovascular disease¹¹, Alzheimer Disease¹², cancer¹³ and glomerular disease¹⁴. Another purpose for biomarker tests is to lead treatment-related actions, such as drug selection, adjustment of drug dosing and timing, and the forecast of possible adverse effects. Posttreatment biomarker tests can provide information through treatment evaluation and potential disease related risks.

The analysis of biomolecules without biomarker identity has undoubted significance. One typical application is therapeutic drug monitoring (TDM)¹⁵⁻¹⁶. Drug blood level is not only determined by the gene expression but also by the environment. The patient's age, body weight, mental condition, or even food and water intake can influence one's short term drug blood concentration significantly. However, the therapeutic window of drugs may not be wide. A rapid, accurate and sensitive drug level measurement can help to improve the optimization of drug dosing and the treatment efficacy,

and at the same time, minimize side effects due to the overdosing. Other typical applications are drug compliance monitoring¹⁷ (increase health care delivery), drug metabolism detection (reduce exceptional adverse effect) and restricted drug control (control the drug of abuse).

Table 1. The classification of clinical biomarker uses and objectives (reprint from reference)¹⁸

Clinical Biomarker Use	Clinical Objective
Screening	Detect and treat early stage disease in the asymptomatic population.
Diagnosis/differential Diagnosis	Definitively establish the presence and precise description of disease.
Classification	Classify patients by disease subset.
Prognosis	Estimate the risk of or the time to clinical outcomes.
Prediction/treatment stratification	Predict response to particular therapies and choose the drug that is most likely to yield a favorable response in a given patient.
Therapy-related risk management	Identify patients with a high probability of adverse effects of a treatment.
Therapy monitoring	Determine whether a therapy is having the intended effect on a disease and whether adverse effects arise.
Posttreatment monitoring	Provide early detection and treatment of advancing disease or complications

In summary, precision medicine has huge advantages over traditional clinical practice and will lead the advancement of future medicine. Precision medicine highly relies on the accuracy and precision of the detection and analysis of biomarkers and biomolecules. The tests of small biomolecules and small molecule biomarkers play an unneglectable role in precision medicine. Many clinical application protocols have been established based on the precision medicine for better prediction, diagnosis, treatment and treatment evaluation.

1.2 Technologies for Small Biomolecule Analysis and Clinical Applications

Different kinds of technologies have been established for the analysis of biomarkers and have their own focus. Computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound are representative imaging methods for organ level imaging. Cytology uses immunostaining, cell biopsy and cell culture followed by microscopic observation to study biomarkers in cellular level.

High-throughput DNA sequencing, *in situ* hybridization and computational genomics are technologies for DNA and RNA level biomarkers that has attracted the world's attention since the beginning of the 21st century. High resolution mass spectrometry like matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)¹⁹, orbitrap²⁰, Fourier transform ion cyclotron resonance (FT-ICR)²¹ were widely used in the 'omics' study such as proteomics, lipidomic and metabolomics²².

The development of technologies for the tests of the small biomolecules are mainly based on immunoassay methods followed by optical observation²³ or chromatographic methods that use UV or mass spectrometry detection.

Immunoassays are based on the binding of antibodies or antigens to analytes in patient samples such as serum, blood or urine. Immunoassays run in two different formats, one is in multiple step mode and the other is a simple one step mode. The multi-step mode separates the analyte by adding reagents and washing it away to achieve separation. Single step immunoassay mixes the analyte and the reagent together and use other physical methods to quantify the result, like optical or colorimetric measurements. Immunoassays also can employ calibrators which contain known concentration of analyte. The comparison of the response of the calibrator and the real sample can provide enough information for a semi-quantitative result.

Liquid chromatograph (LC) and gas chromatograph (GC) followed by UV detector or mass spectrometer are the gold standard of quantitative analysis of small molecules in the past century. As the name implies, the physical state of chromatographic technologies is in either liquid phase or in gas phase. A fluid (either liquid or gas phase) containing dissolved mixture sample is called mobile phase. A structure that fluid passes through but holds another material is called stationary phase. When the mobile phase washes through the stationary phase, molecules travel in different

speeds based upon the partition coefficient between the molecule and stationary phase. Separation is achieved based on the divergent speeds and travel time of different molecules.

However, both immunoassay and chromatography have their drawbacks. Although immunoassay is fast, simple and straight forward, it can only detect one or a specific group of analytes by using one type of assay, and the analysis result can only be semi-quantitative. The test accuracy heavily depends on the PH level and the test time. The sensitivity of immunoassay is mainly determined by the binding energy of antibodies. Chromatography can help to analyze multiple target analytes in a single time with high sensitivity and selectivity; however, it usually has a high purity requirement and needs massive sample preparation. In most cases, sample preparation and instrumentation setup requires a professional operator with a relatively long time to obtain a result. Although chromatography can work as a gold standard in analytical chemistry, it cannot fulfill the requirements needed for precision medicine.

In precision medicine, quantitative results need to be in real time instead of taking hours, to ensure that the treatment or the surgical action can be guided on time. Therefore, immunoassay and chromatography methods are not optimal choices in most cases. The lack of technology and innovation for the real-time quantitative analysis of small biomolecules hinders the progress of precision medicine. An instrument with potential for direct biomolecular quantitative analysis would be beneficial for the implementation of precision medicine.

1.3 Ambient Ionization and Miniature Mass Spectrometer

Ambient ionization mass spectrometry is a technology which minimizes the sample preparation and ionization before sample analysis by mass spectrometry. Analytical conclusions can be obtained in minutes with sufficient specificity and sensitivity. By optimizing the pumping, mass analyzer, ion source and ion transfer components of a portable mass spectrometer, mass